Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Largest borrow rate increases among liquid names » 08:45
09/09/22
09/09
08:45
09/09/22
08:45
FAZE

FaZe Holdings

$13.50 /

+1.4 (+11.57%)

, GETY

Getty Images

$12.41 /

-0.61 (-4.69%)

, NEGG

Newegg Commerce

$3.11 /

-0.15 (-4.60%)

, AVDL

Avadel Pharmaceuticals

$6.05 /

+0.135 (+2.28%)

, EDU

New Oriental Education

$25.96 /

-0.12 (-0.46%)

, PSNY

Polestar

$6.70 /

-0.12 (-1.76%)

, TIGR

UP Fintech

$3.64 /

-0.035 (-0.95%)

, FAZ

Direxion Financial Bear 3x

$21.89 /

-1.235 (-5.34%)

, SOXX

iShares PHLX Semiconductor ETF

$367.09 /

+6.08 (+1.68%)

, IMRA

Imara

$2.13 /

+0.13 (+6.50%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: (FAZE) 1058.11% +262.71, Getty Images (GETY) 955.63% +1.26, Newegg Commerce (NEGG) 61.04% +1.23, Avadel Pharmaceuticals (AVDL) 10.23% +0.75, New Oriental Education (EDU) 1.52% +0.66, Polestar Automotive (PSNY) 272.85% +0.62, UP Fintech Holding Ltd (TIGR) 38.07% +0.46, Financial Bear 3X (FAZ) 19.16% +0.41, iShares PHLX SOX Semiconductor Sector Index Fund (SOXX) 2.21% +0.30, and IMARA (IMRA) 14.02% +0.27.

ShowHide Related Items >><<
TIGR UP Fintech
$3.64 /

-0.035 (-0.95%)

PSNY Polestar
$6.70 /

-0.12 (-1.76%)

NEGG Newegg Commerce
$3.11 /

-0.15 (-4.60%)

IMRA Imara
$2.13 /

+0.13 (+6.50%)

GETY Getty Images
$12.41 /

-0.61 (-4.69%)

FAZE FaZe Holdings
$13.50 /

+1.4 (+11.57%)

FAZ Direxion Financial Bear 3x
$21.89 /

-1.235 (-5.34%)

EDU New Oriental Education
$25.96 /

-0.12 (-0.46%)

AVDL Avadel Pharmaceuticals
$6.05 /

+0.135 (+2.28%)

FAZE FaZe Holdings
$13.50 /

+1.4 (+11.57%)

GETY Getty Images
$12.41 /

-0.61 (-4.69%)

08/25/22 Redburn
Redburn starts Shutterstock with Buy, Getty Images with Neutral
08/25/22 Redburn
Getty Images initiated with a Neutral at Redburn
08/11/22 Benchmark
Getty Images downgraded to Hold from Buy at Benchmark
06/16/22 Benchmark
CC Neuberger Principal Holdings II initiated with a Buy at Benchmark
NEGG Newegg Commerce
$3.11 /

-0.15 (-4.60%)

AVDL Avadel Pharmaceuticals
$6.05 /

+0.135 (+2.28%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
EDU New Oriental Education
$25.96 /

-0.12 (-0.46%)

07/29/22 BofA
New Oriental Education upgraded to Buy from Neutral at BofA
07/28/22 Macquarie
New Oriental Education upgraded to Outperform from Neutral at Macquarie
07/28/22 Daiwa
New Oriental Education price target raised to $32 from $30 at Daiwa
07/14/22 CICC
New Oriental Education upgraded to Outperform from Market Perform at CICC
PSNY Polestar
$6.70 /

-0.12 (-1.76%)

08/01/22 Deutsche Bank
Polestar initiated with a Hold at Deutsche Bank
TIGR UP Fintech
$3.64 /

-0.035 (-0.95%)

06/13/22 Daiwa
UP Fintech price target raised to $5.70 from $5.40 at Daiwa
05/19/22 China Renaissance
UP Fintech assumed with Hold from Buy at China Renaissance
12/01/21 Citi
UP Fintech price target lowered to $7.58 from $18.22 at Citi
10/29/21 Alliance Global Partners
MICT could benefit on top China brokers' fallout, says Alliance Global Partners
FAZ Direxion Financial Bear 3x
$21.89 /

-1.235 (-5.34%)

SOXX iShares PHLX Semiconductor ETF
$367.09 /

+6.08 (+1.68%)

IMRA Imara
$2.13 /

+0.13 (+6.50%)

06/10/22 H.C. Wainwright
Imara transferred with Neutral from Buy at H.C. Wainwright
04/05/22 Citi
Imara downgraded to Neutral from Buy at Citi
03/16/22 SVB Securities
Imara price target lowered to $31 from $37 at SVB Leerink
11/30/21 H.C. Wainwright
Imara initiated with a Buy at H.C. Wainwright
PSNY Polestar
$6.70 /

-0.12 (-1.76%)

NEGG Newegg Commerce
$3.11 /

-0.15 (-4.60%)

IMRA Imara
$2.13 /

+0.13 (+6.50%)

AVDL Avadel Pharmaceuticals
$6.05 /

+0.135 (+2.28%)

PSNY Polestar
$6.70 /

-0.12 (-1.76%)

EDU New Oriental Education
$25.96 /

-0.12 (-0.46%)

PSNY Polestar
$6.70 /

-0.12 (-1.76%)

NEGG Newegg Commerce
$3.11 /

-0.15 (-4.60%)

GETY Getty Images
$12.41 /

-0.61 (-4.69%)

FAZE FaZe Holdings
$13.50 /

+1.4 (+11.57%)

EDU New Oriental Education
$25.96 /

-0.12 (-0.46%)

AVDL Avadel Pharmaceuticals
$6.05 /

+0.135 (+2.28%)

TIGR UP Fintech
$3.64 /

-0.035 (-0.95%)

SOXX iShares PHLX Semiconductor ETF
$367.09 /

+6.08 (+1.68%)

PSNY Polestar
$6.70 /

-0.12 (-1.76%)

NEGG Newegg Commerce
$3.11 /

-0.15 (-4.60%)

GETY Getty Images
$12.41 /

-0.61 (-4.69%)

FAZE FaZe Holdings
$13.50 /

+1.4 (+11.57%)

FAZ Direxion Financial Bear 3x
$21.89 /

-1.235 (-5.34%)

EDU New Oriental Education
$25.96 /

-0.12 (-0.46%)

AVDL Avadel Pharmaceuticals
$6.05 /

+0.135 (+2.28%)

Syndicate
Avadel Pharmaceuticals files $500M mixed securities shelf  16:53
08/31/22
08/31
16:53
08/31/22
16:53
AVDL

Avadel Pharmaceuticals

$6.63 /

+0.06 (+0.91%)

 
ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$6.63 /

+0.06 (+0.91%)

AVDL Avadel Pharmaceuticals
$6.63 /

+0.06 (+0.91%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
AVDL Avadel Pharmaceuticals
$6.63 /

+0.06 (+0.91%)

AVDL Avadel Pharmaceuticals
$6.63 /

+0.06 (+0.91%)

AVDL Avadel Pharmaceuticals
$6.63 /

+0.06 (+0.91%)

Over a month ago
Options
Largest borrow rate increases among liquid names » 08:45
08/12/22
08/12
08:45
08/12/22
08:45
WRBY

Warby Parker

$16.89 /

+2.765 (+19.58%)

, EXPI

eXp World Holdings

$17.75 /

-0.035 (-0.20%)

, NEGG

Newegg Commerce

$3.85 /

+ (+0.00%)

, VTNR

Vertex Energy

$7.04 /

-0.875 (-11.05%)

, SAVA

Cassava Sciences

$19.85 /

+0.03 (+0.15%)

, BCAB

BioAtla

$7.95 /

+1.26 (+18.83%)

, AVDL

Avadel Pharmaceuticals

$6.85 /

-0.27 (-3.79%)

, DWAC

Digital World Acquisition

$30.34 /

+0.07 (+0.23%)

, ENDP

Endo

/

+

, CAN

Canaan

$4.08 /

+ (+0.00%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: Warby Parker (WRBY) 13.35% +2.28, eXp World Holdings (EXPI) 4.08% +0.90, Newegg Commerce (NEGG) 68.02% +0.75, Vertex Energy (VTNR) 5.67% +0.69, Cassava Sciences (SAVA) 42.09% +0.54, BioAtla (BCAB) 1.40% +0.29, Avadel Pharmaceuticals (AVDL) 12.01% +0.28, Digital World Acquisition Corp (DWAC) 50.81% +0.25, Endo (ENDP) 6.77% +0.20, and Canaan Inc (CAN) 1.22% +0.18.

ShowHide Related Items >><<
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

07/22/22 Piper Sandler
Warby Parker initiated with an Overweight at Piper Sandler
07/21/22 Goldman Sachs
Warby Parker price target lowered to $12 from $16 at Goldman Sachs
07/20/22 Stifel
Warby Parker price target lowered to $11 from $15 at Stifel
06/27/22 Loop Capital
Warby Parker price target lowered to $15 from $18 at Loop Capital
EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

08/04/22 DA Davidson
eXp World Holdings price target lowered to $22 from $28 at DA Davidson
05/05/22 DA Davidson
eXp World Holdings price target lowered to $34 from $45 at DA Davidson
NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

08/10/22 Oppenheimer
Vertex Energy downgraded to Perform from Outperform at Oppenheimer
08/10/22 H.C. Wainwright
Vertex Energy price target lowered to $15 from $25 at H.C. Wainwright
07/07/22 Oppenheimer
Vertex Energy initiated with an Outperform at Oppenheimer
06/08/22 Stifel
Vertex Energy price target raised to $20 from $14 at Stifel
SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

08/11/22 B. Riley
Cassava Sciences price target lowered to $44 from $58 at B. Riley
06/02/22 Univest Securities
Univest keeps Sell on Cassava after medical journal retracts article
05/06/22 Univest Securities
Univest says Cassava enrollment still 'severely lags' others in Alzheimer's
05/06/22 B. Riley
Cassava Sciences price target lowered to $58 from $72 at B. Riley
BCAB BioAtla
$7.95 /

+1.26 (+18.83%)

08/10/22 H.C. Wainwright
BioAtla price target lowered to $20 from $25 at H.C. Wainwright
05/05/22 Credit Suisse
BioAtla downgraded to Neutral from Outperform at Credit Suisse
03/21/22 H.C. Wainwright
BioAtla initiated with a Buy at H.C. Wainwright
10/14/21 BTIG
BioAtla assumed with a Buy at BTIG
AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

08/11/22 SVB Securities
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities
08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

ENDP Endo
/

+

05/09/22 BMO Capital
Endo price target lowered to $2 from $4 at BMO Capital
05/09/22 Barclays
Endo price target lowered to $1 from $2 at Barclays
05/06/22 Piper Sandler
Piper downgrades Endo to sell, says 'going from bad to worse'
05/06/22 Piper Sandler
Endo downgraded to Underweight from Neutral at Piper Sandler
CAN Canaan
$4.08 /

+ (+0.00%)

07/06/22 H.C. Wainwright
Canaan initiated with a Buy at H.C. Wainwright
06/07/22 Benchmark
Benchmark starts Canaan with Buy as 'indirect' bitcoin growth play
06/07/22 Benchmark
Canaan initiated with a Buy at Benchmark
05/16/22 DA Davidson
Canaan price target lowered to $10 from $15 at DA Davidson
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

BCAB BioAtla
$7.95 /

+1.26 (+18.83%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

  • 29
    Sep
WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

EXPI eXp World Holdings
$17.75 /

-0.035 (-0.20%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

WRBY Warby Parker
$16.89 /

+2.765 (+19.58%)

VTNR Vertex Energy
$7.04 /

-0.875 (-11.05%)

SAVA Cassava Sciences
$19.85 /

+0.03 (+0.15%)

NEGG Newegg Commerce
$3.85 /

+ (+0.00%)

ENDP Endo
/

+

DWAC Digital World Acquisition
$30.34 /

+0.07 (+0.23%)

CAN Canaan
$4.08 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$6.85 /

-0.27 (-3.79%)

Recommendations
Avadel Pharmaceuticals price target raised to $12 from $6 at SVB Securities » 07:24
08/11/22
08/11
07:24
08/11/22
07:24
AVDL

Avadel Pharmaceuticals

$7.12 /

-0.15 (-2.06%)

SVB Securities analyst…

SVB Securities analyst Ami Fadia raised the firm's price target on Avadel Pharmaceuticals to $12 from $6 and keeps an Outperform rating on the shares. The analyst notes Avadel reported Q2 numbers, and with the recent tentative approval of Lumryz signaling completion of the FDA's review of the NDA, management focused the conference call on the game plan for preparing for commercial launch and potentially accelerating the timeline to final approval of Lumryz.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$7.12 /

-0.15 (-2.06%)

AVDL Avadel Pharmaceuticals
$7.12 /

-0.15 (-2.06%)

08/10/22 Jefferies
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval
08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
AVDL Avadel Pharmaceuticals
$7.12 /

-0.15 (-2.06%)

AVDL Avadel Pharmaceuticals
$7.12 /

-0.15 (-2.06%)

AVDL Avadel Pharmaceuticals
$7.12 /

-0.15 (-2.06%)

Downgrade
Jefferies cuts Avadel to Hold while awaiting Lumryz full approval » 07:59
08/10/22
08/10
07:59
08/10/22
07:59
AVDL

Avadel Pharmaceuticals

$7.27 /

+0.97 (+15.40%)

As previously reported,…

As previously reported, Jefferies analyst Chris Howerton downgraded Avadel Pharmaceuticals to Hold from Buy with a price target of $8, up from $6, stating that the tentative approval of Lumryz assures a Q3 of 2023 launch and the workforce cuts resolve much uncertainty for the path ahead. While he maintains conviction in Lumryz to deliver value in narcolepsy, the stock now appears to price in his base case and he is stepping to the sideline as he sees limited upside given "a fast approaching Goldilocks window" before oxybate generics enter the market in 2025. He is pricing in peak capture of nearly 4,000 narcolepsy patients in 2025 before the market entry of generic oxybate, Howerton noted.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

08/09/22 Jefferies
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies
07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

Downgrade
Avadel Pharmaceuticals downgraded to Hold from Buy at Jefferies » 18:02
08/09/22
08/09
18:02
08/09/22
18:02
AVDL

Avadel Pharmaceuticals

$7.27 /

+0.97 (+15.40%)

Jefferies analyst Chris…

Jefferies analyst Chris Howerton downgraded Avadel Pharmaceuticals to Hold from Buy with a price target of $8, up from $6.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
05/27/22 H.C. Wainwright
Avadel selloff yesterday 'extremely overdone', says H.C. Wainwright
AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

AVDL Avadel Pharmaceuticals
$7.27 /

+0.97 (+15.40%)

Hot Stocks
Avadel Pharmaceuticals sees cash runway to middle of 2023 » 07:15
08/09/22
08/09
07:15
08/09/22
07:15
AVDL

Avadel Pharmaceuticals

$6.30 /

+0.42 (+7.14%)

Cash, cash equivalents…

Cash, cash equivalents and marketable securities were $104.1 million as of June 30, 2022. Subsequent to June, Avadel received $9.9 million of tax refunds and expects to receive an additional $7.3 million of tax refunds. The Company has $26.4 million of convertible debt that matures in February 2023 and $117.4 million that matures in October 2023.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
05/27/22 H.C. Wainwright
Avadel selloff yesterday 'extremely overdone', says H.C. Wainwright
AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

Earnings
Avadel Pharmaceuticals reports Q2 EPS ($1.07), consensus (41c) » 07:13
08/09/22
08/09
07:13
08/09/22
07:13
AVDL

Avadel Pharmaceuticals

$6.30 /

+0.42 (+7.14%)

"The receipt of…

"The receipt of tentative approval from the FDA marks an important milestone in our pursuit to bring LUMRYZ to all oxybate eligible people living with narcolepsy. In addition to validating LUMRYZ's strong clinical and safety profile, we now know the timing to a potential final approval is June 2023 or sooner," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We will continue to aggressively pursue all options for this clear unmet need in the $3 billion plus once nightly oxybate market to accelerate a final approval decision prior to June 2023 and launch as quickly as possible thereafter."

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

07/28/22 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum
07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
05/27/22 H.C. Wainwright
Avadel selloff yesterday 'extremely overdone', says H.C. Wainwright
AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

AVDL Avadel Pharmaceuticals
$6.30 /

+0.42 (+7.14%)

Initiation
Avadel Pharmaceuticals assumed with a Buy at Craig-Hallum » 09:43
07/28/22
07/28
09:43
07/28/22
09:43
AVDL

Avadel Pharmaceuticals

$4.53 /

+ (+0.00%)

Craig-Hallum analyst…

Craig-Hallum analyst Chase Knickerbocker assumed coverage of Avadel Pharmaceuticals with a Buy rating with a price target of $12, down from $15.50, citing his "slightly more conservative" revenue ramp estimates. Avadel has five quarters of cash, with full approval for Lumryz to come within four quarters regardless of patent outcome, contends Knickerbocker, who thinks the stock is currently being mispriced and believes owning the stock now before full approval "generates upside" even if the company needs capital for a commercial launch. "Even in the worst-case scenario we see more than 2x upside as Lumryz and its 1x/nightly dosing becomes a dominant player in the narcolepsy market," the analyst added.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$4.53 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$4.53 /

+ (+0.00%)

07/19/22 Stifel
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel
05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
05/27/22 H.C. Wainwright
Avadel selloff yesterday 'extremely overdone', says H.C. Wainwright
05/26/22 Stifel
Stifel downgrades Avadel despite 59% selloff on launch delay
AVDL Avadel Pharmaceuticals
$4.53 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$4.53 /

+ (+0.00%)

AVDL Avadel Pharmaceuticals
$4.53 /

+ (+0.00%)

Recommendations
Avadel Pharmaceuticals price target raised to $5 from $2 at Stifel » 13:46
07/19/22
07/19
13:46
07/19/22
13:46
AVDL

Avadel Pharmaceuticals

$4.63 /

+0.405 (+9.59%)

Stifel analyst Paul…

Stifel analyst Paul Matteis raised the firm's price target on Avadel Pharmaceuticals to $5 from $2 and keeps a Hold rating on the shares. The analyst remains on the sidelines following the announcement that FT218 has received tentative approval. While "encouraging," Matteis still views a path to accelerating a full approval as unlikely. Separately, while the valuation is "fairly cheap" for a tentative approved commercial asset in a big market, there are "complicating factors" in his view including launch costs and building/supporting a REMS, Avadel's cash needs with converts due 2023, residual ODE questions, and oxybate market dynamics which are becoming increasingly challenging.

ShowHide Related Items >><<
AVDL Avadel Pharmaceuticals
$4.63 /

+0.405 (+9.59%)

AVDL Avadel Pharmaceuticals
$4.63 /

+0.405 (+9.59%)

05/27/22 Craig-Hallum
Avadel Pharmaceuticals price target lowered to $15.50 from $20 at Craig-Hallum
05/27/22 H.C. Wainwright
Avadel selloff yesterday 'extremely overdone', says H.C. Wainwright
05/26/22 Stifel
Stifel downgrades Avadel despite 59% selloff on launch delay
05/26/22 Stifel
Avadel Pharmaceuticals downgraded to Hold from Buy at Stifel
AVDL Avadel Pharmaceuticals
$4.63 /

+0.405 (+9.59%)

AVDL Avadel Pharmaceuticals
$4.63 /

+0.405 (+9.59%)

AVDL Avadel Pharmaceuticals
$4.63 /

+0.405 (+9.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.